Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 6/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567651 | 0.85 | KCNH2 (0.46) | KCNH2MAP4K4PIK3CAMINK1PI4KB | |
| SCHEMBL25408338 | 0.85 | KCNH2 (0.46) | KCNH2MAP4K4PIK3CAMINK1PI4KB | |
| SCHEMBL26849009 | 0.81 | SLC34A1 (0.43) | KCNH2MAP4K4PIK3CAMINK1PI4KB | |
| SCHEMBL26847489 | 0.81 | HDAC3 (0.39) | CYP3A4CYP2C9CYP2C19LMNACRHR1 | |
| SCHEMBL26847563 | 0.76 | JMJD6 (0.43) | — | |
| SCHEMBL8322070 | 0.73 | LMNA (0.55) | CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL25406855 | 0.72 | KCNH2 (0.48) | KCNH2MAP4K4PIK3CAMINK1PI4KB | |
| SCHEMBL30567672 | 0.72 | KCNH2 (0.48) | KCNH2MAP4K4PIK3CAMINK1PI4KB | |
| SCHEMBL17247907 | 0.72 | CYP2A6 (0.53) | KCNH2MAP4K4PIK3CAMINK1PI4KB | |
| SCHEMBL31663301 | 0.71 | USP1 (0.34) | KCNH2PIK3CATRPV3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | KCNH2 4708/4885RAD51 2735/4885MAP4K4 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.